Formycon 대차 대조표 상태

재무 상태 기준 확인 5/6

Formycon 의 총 주주 지분은 €427.4M 이고 총 부채는 €0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 €912.9M 및 €485.5M 입니다.

주요 정보

부채 비율

€0

부채

이자 보상 비율	n/a
현금	€36.87m
주식	€427.42m
총 부채	€485.53m
총 자산	€912.94m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: FYBD 의 단기 자산 ( €83.4M )이 단기 부채( €82.1M ).

장기 부채: FYBD 의 단기 자산( €83.4M )은 장기 부채( €403.4M ).

부채 대 자본 내역 및 분석

부채 수준: FYBD 부채가 없습니다.

부채 감소: FYBD 5년 전에 부채가 없었습니다.

부채 범위: FYBD 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: FYBD 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Formycon 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Formycon AG Appoints Colin Bond as Director

Fresenius Kabi and Formycon Receives U.S. FDA Approval for Biosimilar Otulfi (ustekinumab-aauz)

Formycon AG to Report First Half, 2024 Results on Aug 13, 2024

Formycon AG to Report Q1, 2024 Results on May 08, 2024

Formycon AG to Report Fiscal Year 2023 Final Results on Apr 25, 2024

Formycon AG has completed a Follow-on Equity Offering in the amount of €82.840247 million.

Formycon AG to Report First Half, 2023 Results on Aug 30, 2023

Formycon Announces Submission of the Biologics License Application (Bla) for Fyb203, an Aflibercept Biosimilar Candidate to the U.S. Food and Drug Administration (Fda)

Full year 2022 earnings released: EPS: €2.62 (vs €1.22 loss in FY 2021)

Formycon AG has completed a Follow-on Equity Offering in the amount of €70.07 million.

Formycon AG Publishes Details of A Previously Undisclosed Pipeline Project – Fyb206 Is A Biosimilar Candidate for Keytruda (Pembrolizumab)

Formycon AG, Polpharma Biologics Group BV and Bioeq AG Announce European Commission Approval for FYB201/Ranivisio1 (Ranivisio - Ranibizumab), a Biosimilar to Lucentis2 (News with Additional Features)

Formycon Ag Announces EU-Approval of FYB201/Ranivisio A Biosimilar to Lucentis

Formycon's Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara in Phase III Study

Formycon Announces FDA Approval of Fyb201/Cimerlitm1 (Ranibizumab-EQRN) as A Biosimilar Interchangeable with Lucentis®2

Formycon AG Announces Supervisory Board and Executive Changes

Formycon's Biosimilar for Lucentis (Ranibizumab), Receives CHMP Recommendation from EMA

Forecast breakeven date pushed back to 2023

Formycon AG Announces Changes to Its Executive Board

Formycon AG Announces Receipt of Market Authorization of from Medicines and Healthcare Products Regulatory Agency

Formycon AG Provides Revenue Guidance for the Year 2021

Formycon AG and Bioeq AG Announce Submits Biologics License Application for FYB201 to U.S. Food and Drug Administration

Formycon AG Provides Sales Guidance for the Fiscal Year 2021

Formycon Receives Approval for Early Action for COVID-19 Drug FYB207 as Part of a Grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy

Formycon Receives Positive Scientific Advice from Paul-Ehrlich-Institute for the COVID-19 Drug FYB207 and Assures GMP Manufacturing Capacities

Formycon AG, Annual General Meeting, Sep 27, 2021

Formycon's Scientific Collaboration Partners Present FYB207 Results At International Keystone Symposium

New 90-day high: €47.00

Formycon AG and Bioeq GmbH Announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara(R) (Ustekinumab)

Formycon AG and Bioeq AG Announce Biologics License Application Resubmission Strategy for Fyb201 Has Been Adjusted

Formycon AG to Report Q1, 2020 Results on Jun 22, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기